Canaccord Genuity Group Increases Corcept Therapeutics (NASDAQ:CORT) Price Target to $142.00
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) had its price objective hoisted by analysts at Canaccord Genuity Group from $130.00 to $142.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target points to a potential upside of […]
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) had its price objective hoisted by analysts at Canaccord Genuity Group from $130.00 to $142.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target points to a potential upside of […]
